A dysfunction of the orexin (hypocretin) system in the hypothalamus has recently been linked to the pathogenesis of narcolepsy. The authors used in vivo proton MR spectroscopy to assess the N-acetylaspartate (NAA) content in the hypothalamus of narcoleptic patients. Hypothalamic NAA/creatine-phosphocreatine was reduced in narcoleptic patients compared with control subjects (p Ͻ 0.01). Hypothalamic neuronal loss/damage is a central pathogenetic feature in narcolepsy.
Narcolepsy affects~1 in 2,000 individuals and is characterized by excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic hallucinations, and disturbed nocturnal sleep. 1 Cataplexy, a sudden muscle tone loss brought on by emotions, is a clinical feature almost exclusive to narcolepsy that occurs in~60% of patients. 2, 3 The diagnosis is based on the occurrence of sleep-onset REM periods (SOREMPs) during the multiple sleep latency test (MSLT). The presence of human leukocyte antigen (HLA)-DQB1*0602 is supportive of the diagnosis. A dysfunction of the orexin (hypocretin) system in the hypothalamus has recently been linked to the pathogenesis of narcolepsy. 4 A severe reduction in hypothalamic orexin-containing neurons and axons 5, 6 and regions of gliosis, maximal in the posterior and tuberomammillary hypothalamic area, 6, 7 was detected in narcoleptic patients. Conversely, the large majority of narcoleptic patients with cataplexy do not show detectable orexin in their CSF. 8 A recent MR study using the voxel-based morphometry (VBM) technique disclosed a marked bilateral decrease in the hypothalamic gray matter content in narcolepsy patients. 9 Proton MR spectroscopy ( 1 H-MRS) allows the noninvasive and spatially resolved measurement of several brain compounds, including N-acetylaspartate (NAA), a neuronal marker that is reduced when neuronal loss or damage occurs as in neurodegenerative, inflammatory, or vascular disorders. 10 In the present study, we used 1 H-MRS to detect in vivo evidence of neuronal loss in the hypothalamus of narcoleptic patients with or without cataplexy.
Patients and methods. We studied 23 HLA-DQB1*0602positive narcoleptic patients (table 1) diagnosed according to the International Classification of Sleep Disorders (ICSD) criteria 1 and 10 healthy control subjects (6 men; mean age, 37 Ϯ 14 years). All patients underwent 5 days of continuous polysomnographic recording followed by MSLT, confirming in all shortened sleep latency and multiple SOREMPs. In 10 patients with a history of narcolepsy with cataplexy, cataplectic attacks were documented on video-polysomnography. Patients taking medications (16/23) withdrew drugs 20 days before hospital admission. Informed consent was obtained from all subjects, and studies were performed with the approval of the local ethics committee.
MR studies were performed in a 1.5-T GE Signa Horizon LX scanner (Waukesha, WI) using a quadrature birdcage head coil. MRIs were obtained by acquiring contiguous 3-mm-thick axial fast gradient-echo (repetition time [TR], 250 ms; echo time [TE], 2.5 ms) and sagittal fast spin-echo images (TR, 600 ms; TE, 12 ms). A volume of interest (VOI) ranging from 1 to 1.2 cm 3 was selected to include bilateral hypothalamic gray matter ( figure 1A ). Water-suppressed proton MR spectra were acquired using the PRESS single-voxel localization sequence (TR, 1,500 ms; TE, 40 ms; number of acquisitions, 1,536). In 20 (8 with cataplexy) of the 23 patients, an additional spectrum was also acquired from the midline parieto-occipital cortex (VOI, 18 cm 3 ; TR, 4,000 ms; TE, 35 ms).
Peak areas for NAA at 2.02 parts per million (ppm), creatinephosphocreatine (Cr) at 3.03 ppm, choline (Cho) at 3.22, and mio-Inositol (mI) at 3.56 ppm were calculated using the time domain fitting program AMARES/MRUI (http://carbon.uab.es/mrui). Peak integral values were expressed relative to the Cr peak.
Significance, determined by the nonparametric Mann-Whitney U test or the Fisher's protected least significant difference test (analysis of variance), was taken as p Ͻ 0.05.
Results.
A reduction in NAA/Cr was found in the hypothalamus of narcoleptic patients (mean Ϯ SD, 1.45 Ϯ 0.17) compared with controls (1.62 Ϯ 0.17; p ϭ 0.009; figure 1B and figure 2A ). Dividing our patients into those with narcolepsy and those with narcolepsy associated with cataplexy (see table 1), the hypothalamic NAA/Cr was lower in narcoleptic patients with cataplexy (1.37 Ϯ 0.14) than in narcoleptic patients without cataplexy (1.51 Ϯ 0.16; p ϭ 0.03), who in turn failed to show a hypothalamic NAA/Cr reduction compared with healthy control subjects (p ϭ 0.1; figure 2B ). NAA/Cr was less than the normal range (1.44 to 2.01) in 8 of 10 patients with cataplexy and in 3 of 13 patients without cataplexy (see figure 2B ). Despite differences in NAA/Cr content, patients without and with cataplexy showed similar clinical and MSLT-polysomnographic features (see table 1 ). In the patients, Cho/Cr (1.26 Ϯ 0.17) and mI/Cr (0.96 Ϯ 0.20) were similar to that found in control subjects (Cho/Cr, 1.24 Ϯ 0.13, p ϭ 0.6; mI/Cr, 0.94 Ϯ 0.15, p ϭ 0.7).
In the parieto-occipital cortex of the patients, NAA/Cr (1.43 Ϯ 0.08), Cho/Cr (0.66 Ϯ 0.07), and mI/Cr (0.64 Ϯ 0.11) were not different from the values found in healthy volunteers (NAA/Cr, 1.44 Ϯ 0.07, p ϭ 0.6; Cho/Cr, 0.68 Ϯ 0.07, p ϭ 0.7; mI/Cr, 0.66 Ϯ 0.09, p ϭ 0.7). Cortical NAA/Cr did not show a difference between narcoleptic patients with (1.46 Ϯ 0.08) and without cataplexy (1.41 Ϯ 0.07; p ϭ 0.16), who in turn did not differ from control subjects (p ϭ 0.6 for patients with cataplexy and p ϭ 0.3 for patients without). The findings were similar for cortical Cho/Cr and mI/Cr (data not shown).
In the patients, no significant correlation was found Discussion. The reduced NAA content found in the hypothalamus of narcoleptic patients is direct evidence that hypothalamic neuronal loss/damage is a central pathogenetic feature in narcolepsy. In narcoleptic patients, cortical NAA content was not reduced, indicating the selective involvement of the hypothalamus.
The hypothalamic NAA-to-Cr ratio was significantly lower in the narcoleptic patients with cataplexy than in narcoleptic patients without cataplexy, in whom the NAA-to-Cr ratio reduction failed to reach significance compared with healthy control subjects (see figure 2B ). Hypothalamic NAA/Cr was less than the normal range in 80% of cataplectic patients and only in 23% of narcoleptics without cataplexy. Pathophysiologic differences between narcoleptic patients with and without documented cataplexy are consistent with differences in the extent of orexin system impairment in the two subgroups of patients. Most narcoleptic patients without cataplexy have normal CSF concentrations of orexin, 8 whereas Ͼ90% of narcoleptic subjects with typical cataplexy have no detectable orexin in their CSF. 8 Among the six brains from narcoleptic patients studied pathologically, the only case without cataplexy had the largest number of remaining hypothalamic orexin neurons compared with the five patients with cataplexy. 5, 6 Our present 1 H-MRS findings may suggest a more widespread cell loss than that demonstrated pathologically in narcoleptic patients. [5] [6] [7] However, besides neuronal loss, an increased number of glial cells 7 (containing Cr but not NAA) and dysfunction of neurons 10 functionally related to hypocretin-containing neurons (like hypothalamic histamine cells 7 ) could also have contributed to the reduction in hypothalamic NAA/Cr we found in narcoleptic patients.
The cause of neuronal loss in narcolepsy is not known. Hypothalamic NAA-to-Cr ratio in our narcoleptic patients failed to show a correlation with clinical, polysomnographic, and MSLT features other than cataplexy. Although this finding could suggest an acute/ subacute event (cytotoxic or immunologically mediated 7 ), a neurodegenerative process that becomes clinically evident only when a large majority of orexincontaining neurons are lost cannot be excluded. The greater severity of hypothalamic NAA/Cr reduction in patients with narcolepsy with cataplexy compared with those without adds to the pathologic and CSF evidence that these may be two somewhat different conditions. Narcoleptic patients without cataplexy, who had a mean hypothalamic NAA/Cr less than that in control subjects (but not reaching significance), might have a residual number of hypothalamic orexin-containing neurons accounting for the slighter disease severity (marked EDS but no clear-cut cataplexy).
The data reported characterize in vivo the neuroanatomic substrate underlying narcolepsy by providing evidence of neuronal loss in the hypothalamus of narcoleptic patients with cataplexy and possibly in narcoleptic patients without cataplexy. Longitudinal 1 H-MRS follow-up evaluation of narcoleptic patients from the disease onset should be performed to disclose the temporal evolution of the pathologic abnormalities. 
